- Home
- FLNG vs AUPH Comparison
FLNG vs AUPH Comparison
Compare FLNG & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLNG | AUPH |
|---|---|---|
| Founded | 2006 | 1993 |
| Country | Bermuda | Canada |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | FLNG | AUPH |
|---|---|---|
| Price | $29.43 | $15.00 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $23.00 | $17.25 |
| AVG Volume (30 Days) | 568.9K | ★ 792.3K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 10.25% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 2.07 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | N/A | $17.35 |
| Revenue Next Year | $3.17 | $15.66 |
| P/E Ratio | $19.72 | ★ $6.85 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $19.46 | $6.83 |
| 52 Week High | $29.26 | $16.54 |
Technical Indicators
Market Signals| Indicator | FLNG | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 74.44 | 58.29 |
| Support Level | $24.61 | $14.56 |
| Resistance Level | N/A | $15.23 |
| Average True Range (ATR) | 0.75 | 0.51 |
| MACD | 0.23 | 0.05 |
| Stochastic Oscillator | 98.30 | 93.83 |
Price Performance
Historical ComparisonAbout FLNG FLEX LNG Ltd.
Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The fleet consists of thirteen modern LNG ships, ten existing and three under construction for delivery. All LNG carriers are equipped with slow-speed, two-stroke engines MEGI or X-DF propulsion which will provide Charterers with tonnage offering advantages in form of reduced fuel consumption and lowered boil-off rates.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.